The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.00
Bid: 27.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 2.00 (7.407%)
Open: 28.00
High: 28.00
Low: 28.00
Prev. Close: 28.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Apr 2013 07:00

RNS Number : 4075C
Ilika plc
16 April 2013
 



 

Ilika plc

("Ilika" or the "Company")

 

Trading Update

 

Ilika (AIM: IKA), the advanced cleantech materials discovery company, provides the following trading update for the financial year ending 30 April 2013.

 

Operational Review

The main focus of Ilika's technology development remains on its solid-state lithium-ion battery technology, for which it successfully raised funds in April 2012. Progress remains on schedule with further tests on the prototype cells being conducted to ensure that the technology is as robust as possible and to continue to improve performance. It is currently filing additional intellectual property in the area to protect its proprietary position.

 

Following the announcement in December 2012, that the Company had received the grant of a key patent covering its novel fuel cell catalyst compositions in the US, Ilika has submitted positive cell performance data and material samples for evaluation by select automotive manufacturers based primarily in the US and Japan. Furthermore, Ilika's development partner in Taiwan has now successfully manufactured the catalyst material, which is a critical component of the battery cell, to Ilika's specification at the kilogram scale. This development progress ensures that the industrial production process can be readily transferred to any volume manufacturing partner.

 

Relationships with our other development partners and end customers across our other material development programmes remain strong, with announcements regarding renewals with its largest customer having been made in December 2012 and February 2013. Further such renewals are expected to continue in the coming financial year.

 

Financial Review

Despite significant operational progress across all its IP development programmes, the Company has experienced order delays with three unrelated contracts. Two of the contracts are from new customers in the US and the third is from a new customer in Europe. These are in the area of battery technology and structural materials. All three contracting processes are still live and the Company will update the market as soon as further news is available.

 

As a direct consequence of these delays, it is expected that revenue for the year ending 30 April 2013 will be approximately £1.1m (2012: £2.0m). This reduction in revenue expectation is directly reflected in a reduced EBITDA expectation (Earnings before Interest, tax, depreciation, amortisation and share based payments), which will be a loss of approximately £3.2m (2012: £1.8m). The loss before tax is expected to be approximately £4m (2012: £2.8m).

 

Following the successful expansion of facilities and infrastructure, cash balances will amount to approximately £1.8m at 30 April 2013 (2012: £5.3m). Overheads have been reduced following the successful disposal of Ilika's wound care operations, as announced in December, and costs will continue to be closely managed going forward.

 

Outlook

Budgeting in the next financial year will reflect the more conservative deal conversion rates and longer timelines experienced in this financial year. Consequently, lower sales are forecast relative to previous expectations, but are underpinned by mature sales prospects.

 

In the coming financial year, the Company expects to reap the benefits of the infrastructure and development investments already made.

 

Ilika expects to announce its audited full year results for the year ended 30 April 2013 on or around 15 July 2013.

 

Commenting on the Trading Update, Graeme Purdy, Ilika's Chief Executive, said: "We are disappointed with the delays in acquiring new customers that are impacting this year's financial performance. However, we are encouraged by the significant progress made in the development of our solid state battery technology and the initial reception given by the international automotive industry to our low cost fuel cell catalyst. Feedback from our customers is indicating sustained demand for innovation in both battery and fuel cell technologies to reduce the cost point for energy storage and motive power. This year has provided a strong springboard for further commercialisation milestones and revenue growth going forward. Further guidance will be given with our annual results in July."

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan, Nominated Adviser

 

James Black, Corporate Broking

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or ilika@walbrookpr.com

Paul McManus

07980 541 893

Paul Cornelius

07827 879 460

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSFAFWIFDSEIL
Date   Source Headline
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn
17th Nov 20229:00 amRNSPrice Monitoring Extension
17th Nov 20227:01 amRNSAppointment of Chief Financial Officer
17th Nov 20227:00 amRNSTrading Update, Notice of Results & Presentations
22nd Sep 202212:45 pmRNSExercise of Options, PDMR Shareholding and TVR
20th Sep 20224:47 pmRNSResult of AGM
7th Sep 202210:00 amRNSGoliath Scale-up Update
18th Aug 20227:00 amRNSPosting of Annual Report and Notice of AGM
1st Aug 20229:05 amRNSSecond Price Monitoring Extn
1st Aug 20229:00 amRNSPrice Monitoring Extension
25th Jul 20223:30 pmRNSHolding(s) in Company
20th Jul 20222:05 pmRNSSecond Price Monitoring Extn
20th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 20227:00 amRNSExercise of Options and Total Voting Rights
13th Jul 20224:41 pmRNSSecond Price Monitoring Extn
13th Jul 20224:36 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSGoliath Scale-up Update
11th May 20227:00 amRNSTrading Update & Notice of Results
4th May 20227:00 amRNSGoliath Scale-up Update
21st Mar 202211:45 amRNSDirector/PDMR Shareholding
15th Mar 202212:34 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSDirectorate Change
24th Feb 20222:01 pmRNSPrice Monitoring Extension
8th Feb 20227:00 amRNSAward of Share Options
7th Feb 202211:01 amRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSFirst Stereax Manufacturing Facility Opened
23rd Nov 20215:11 pmRNSHolding(s) in Company
19th Nov 20217:00 amRNSTrading Update & Notice of Half-year Results
10th Nov 20217:00 amRNSCapital Markets Day
22nd Sep 20213:30 pmRNSResult of AGM and Award of Bonus Share Options
10th Sep 20217:00 amRNSCommencement of trading on OTCQX Best Market in US
7th Sep 20217:00 amRNSSenior Appointments and Change of Director
24th Aug 20217:00 amRNSStereax Manufacturing Update
20th Aug 20217:00 amRNSNotice of AGM & Posting of Annual Report
5th Aug 20219:16 amRNSExercise of Options and Total Voting Rights
30th Jul 20214:32 pmRNSHolding(s) in Company
30th Jul 20219:54 amRNSDirector/PDMR Shareholding
29th Jul 20219:00 amRNSExercise of Options and Total Voting Rights
28th Jul 20211:14 pmRNSResults of GM, Open Offer and Total Voting Rights
12th Jul 202112:30 pmRNSPosting of Circular
9th Jul 20214:07 pmRNSResult of Placing and Retail Offer
9th Jul 20217:01 amRNSRetail Offer
9th Jul 20217:00 amRNSProposed Placing, Open Offer and Retail Offer
6th Jul 20217:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.